Trial Profile
Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jan 2023
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Non-radiographic axial spondyloarthritis
- Focus Pharmacodynamics; Registrational; Therapeutic Use
- Acronyms C-AXSPAND
- Sponsors UCB; UCB Biosciences
- 14 Nov 2022 Results of post hoc analysis assessing baseline MRI and CRP status impacted long-term (3-year) clinical responses to certolizumab pegol, presented at the ACR Convergence 2022.
- 04 Jun 2022 Results of post hoc analysis evaluating whether patients baseline MRI and CRP status impacted long-term (3-year) clinical responses to CZP, presented at the 23rd Annual Congress of the European League Against Rheumatism
- 09 Nov 2021 Results presented at the ACR Convergence 2021